362

the group consisting V3FucnLc6, IlI3FucnLc6, and llI3V3VIl3Fuc3nLc8.

PATENT ABSTRACTS

of III3FucnLc4, 5171836 III3V3Fuc2nLc6,

A N T I B I O T I C S P L U S B A C I N

5171677

RECOMBINANT MAREK'S DISEASE VIRUS AND PROCESS

FOR PREPARING THE SAME

Masash Sakaguchi, Hiroaki Maeda, Michitaka Yamamoto, Junichi Miyazaki, Kumamoto, Japan assigned to Juridical Foundation The Chemo-Sero-Therapeutic Research Institute

A recombinant Marek's disease virus which comprises a Marek's disease virus genom and a DNA fragment incorporated therein, said DNA fragment being constructed by incorporating a promoter derived from an animal cell or an animal virus and a structural gene coding for an exogenous protein into a gene fragment derived from a Marek's disease virus, a process for pre- paring the same which comprises preparing a gene fragment wherein a structural gene coding for an exogenous gene is linked to the dow- nstream of a promoter derived from an animal cell or an animal virus, incorporating said gene fragment into a BamHI - H fragment ofa gene of a Marek's disease virus type I, and incorporating said fragment into a Marek's disease virus type I genome, and a multivalent live vaccine for birds comprising the same.

5171685

C L O N I N G O F T H E B A B E S I A B O V I S 60 K D A N T I G E N

Terry F McElwain, Stephen A Hines, Travis C McGuire, Guy Palmer, Douglas P Jasmer, David W Reduker, Will Goff, Lance E Per- ryman, William C Davis assigned to University of Florida; The United States of America as represented by the United States Department of Agricultu

The subject invention concerns the identifica- tion of novel merozoite surface proteins of Babesia bovis. Also disclosed are monoclonal antibodies to these proteins as well as genes which encode for the proteins. The invention fur- ther concerns the use of the novel proteins, recombinant DNA clones, and monoclonal anti- bodies in the detection, treatment, and pro- phylaxis of babesiosis.

Tadash Yoshida, Jun'ichi Shoji, Teruo Hattori, Koichi Matsumoto, Osaka, Japan assigned to Shionogi & Co Ltd

This invention provides a novel compound of the formula: See Patent for Chemical Structure wherein X is L-HyPro or L-Pro, R is -CH3 or - CH(CH3)2, and n is an integer from 9 to 12, or its salt, a process for producing the compound which comprises cultivating a microorganism which belongs to the genus Pseudomonas and produces the compound in a medium and recovering the compound from the medium and a biologically pure culture of Pseudomas sp. PB- 6250 producing the compound.

5171838

L E U 3 A B I N D I N G P E P T I D E S

Yukinobu Chiba, Tokyo, Japan assigned to Kureha Kagaku Kogyo Kabushiki Kaisha

Compositions comprising peptide analogues of a CD4 epitope capable of interacting with a monoclonal antibody designated Leu3a or with the envelope glycoprotein (gp 120) of the human immunodeficiency virus (HIV) are provided. In a preferred embodiment, the peptide will consist of the amino acid sequence: ser-lys-leu-asn-asp- arg-ala-asp ser-arg-arg-ser-leu-trp-asp. The in- vention also includes a series of peptides having one or more D-amino acid substitution that con- fer enhanced resistance to degradation in serum. Pharmaceutical compositions and methods for using the peptides in therapeutic applications are also provided.

5171839

N U C L E O T I D E A N D A M I N O A C I D S E Q U E N C E S O F P R O T E I N M T P 4 0

O F M. T U B E R C U L O S I S A N D S Y N T H E T I C P E P T I D E S D E R I V E D

T H E R E F R O M

Manuel E Patarroyo, Bogota, Colombia

The present invention relates to novel chem- ically synthesized nucleotides and novel chem- ically synthesized peptides which have been found to be effective in assaying for the presence of M. tuberculosis.